ATP-noncompetitive CDK inhibitors for cancer therapy: an overview

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.7, 2013-11, pp. : 895-906

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents

Current Medicinal Chemistry, Vol. 22, Iss. 2, 2014-12 ,pp. : 237-263

Bentham Science Publishers

Access to resources Recommend Favorite

Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging

Mini Reviews in Medicinal Chemistry, Vol. 10, Iss. 6, 2010-06 ,pp. : 527-539

Bentham Science Publishers

Access to resources Recommend Favorite

CDK inhibitors in clinical development for the treatment of cancer

By Fischer Peter M Gianella-Borradori Athos

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 6, 2003-06 ,pp. : 955-970

Informa Healthcare

Access to resources Recommend Favorite

VEGF Inhibitors in Cancer Therapy

Current Pharmaceutical Design, Vol. 12, Iss. 3, 2006-01 ,pp. : 387-394

Bentham Science Publishers

Access to resources Recommend Favorite

Proteasome Inhibitors in Cancer Therapy

Current Drug Targets, Vol. 10, Iss. 10, 2009-10 ,pp. : 968-981

Bentham Science Publishers

Access to resources Recommend Favorite